Clinical data
ATC code none
CAS Number 110623-33-1 YesY
PubChem (CID) 25431
ChemSpider 23743 N
UNII 3H7H68317X YesY
KEGG D05980 YesY
Chemical and physical data
Formula C10H10FN3S
Molar mass 223.269 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM.[1] It was investigated for the treatment of depression and Alzheimer's disease,[2] but clinical development seems to have been discontinued.


  1. Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM (September 1992). "MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties". Br. J. Pharmacol. 107 (1): 78–86. doi:10.1111/j.1476-5381.1992.tb14466.x. PMC 1907590Freely accessible. PMID 1330168.
  2. Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ (May 1997). "Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers". Biopharm Drug Dispos. 18 (4): 325–34. doi:10.1002/(SICI)1099-081X(199705)18:4<325::AID-BDD21>3.0.CO;2-1. PMID 9158880.

This article is issued from Wikipedia - version of the 6/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.